Compare CBSH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBSH | CELC |
|---|---|---|
| Founded | 1865 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.0B |
| IPO Year | 2008 | 2017 |
| Metric | CBSH | CELC |
|---|---|---|
| Price | $59.02 | $115.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $58.28 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 4.39 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.43 | N/A |
| Revenue Next Year | $3.43 | $720.19 |
| P/E Ratio | $61.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.99 | $13.36 |
| 52 Week High | $66.31 | $151.02 |
| Indicator | CBSH | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 72.30 | 64.52 |
| Support Level | $51.60 | $98.31 |
| Resistance Level | $60.21 | $117.61 |
| Average True Range (ATR) | 0.93 | 5.25 |
| MACD | 0.19 | 3.60 |
| Stochastic Oscillator | 93.74 | 93.62 |
Commerce Bancshares Inc operates as the bank holding company for Commerce Bank. The bank is engaged in the general banking business, providing a broad range of retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals, businesses, and municipalities. The company has three reportable segments. The Commercial segment provides lending, leasing, deposit, payment, and cash management services to business and government customers. The Retail Banking segment offers consumer deposits, consumer lending, mortgage banking, and debit and credit card services through its branch network. The Wealth segment provides trust, estate planning, brokerage, and investment management services to individual and institutional clients.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.